-+ 0.00%
-+ 0.00%
-+ 0.00%

OKYO Pharma Director John Brancaccio Buys 5,000 Shares At An Average Price Of $1.61, Raising Total Holdings to 31,201

Benzinga·03/19/2026 14:06:14
Listen to the news

OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and for inflammatory eye diseases, today announced it has been informed that John Brancaccio, Non-Executive Director, has acquired 5,000 of the Company's ordinary shares on NASDAQ at $1.61, bringing his total holding to 31,201 shares.